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Goal
Provision of a safe and effective medication formulary that treats the 
conditions that arise in exploration spaceflight
• Safety/Toxicity/Degradants
• Effectiveness/Stability/API (Active Pharmaceutical Ingredient)
– USP determines standard for stability
– Typically API within 10% of specification
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Prior Studies
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Blue et al. Supplying a Pharmacy for NASA Exploration Spaceflight: 
Challenges and Current Understanding. Npj Microgravity. (2019)5:14.
Risk of Ineffective or Toxic Medications due to Long Term 
Storage
• Given that there is no current 
method to sufficiently characterize 
medication use, drug quality and 
performance, clinical outcomes, 
and the impact of a hostile space 
environment on pharmaceutical 
stability and potency during long-
duration exploration missions, 
there is a possibility that provision 
of a safe and effective drug 
treatment will be significantly 
limited, impacting crew health and 
performance.
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5A Particular Challenge for 
Exploration Missions
• Minimal to no resupply
• Longer mission durations
• Longer exposure to space environment (for both 
humans and meds)
• Medical conditions more consequential
Three Primary Questions
1. How do we package/store medications?
2. How do we pick which medications study?
3. How are those medications impacted by spaceflight?
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Packaging and Storage
• Historically, medications typically 
repackaged on ground prior to 
flight for operational reasons 
(volume, convenience of use)
• Terrestrially, re-packaging 
invalidates manufacturer’s stated 
shelf life
• In flight, re-packaging may lead to 
increased exposure to flight 
environment (radiation, humidity, 
temperature, CO2, etc.) that 
accelerates degradation process
• Insert Photo of re-packaged 
meds
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Packaging and Storage
• Four Options:
– Manufacturer’s packaging
– Re-packaging as currently done for ISS
– Novel packaging/storage strategies (e.g. nitrogen purge, ceramic coating, just-in-time manufacture)
– Shielding or environmental control chambers
• Optimize among competing factors:
– Preserve API
– Minimize degradants/toxicity
– Minimize resource footprint (mass, volume, power, etc.) 
• Understand feasibility:
– Technical
– Operational
– Economic
– Regulatory
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Exploration Candidate Formulary
1. ExMC Pharmacy Research 
Prioritized Medication List –
2019
2. Supplement with:
– Conditions from LOC IV/V Accepted 
Medical Condition List
– Condition -> Capability -> Resource 
tracings from medical system SysML
model
3. Final inputs from IMPACT trade 
space tool results
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Data gathering for medications on the Exploration Candidate Formulary
• Create Pharmacy Information 
Database
– Spaceflight data
– Analog data (e.g. NSRL)
– Terrestrial data (e.g. FDA)
Data attributes include: 
– Drug Product – generic name
– Strength
– Dosage form
– Therapeutic Classification
– Chemical Structure (API)
– Chemical Class (API)
– API Drug Degradation pathways (chemical reactions)
– API Degradation Products
– API Degradation Product structure (Toxic Y/N)
– Environmental sensitivities (light/UV, temperature, 
humidity, radiosterilization) 
– Shelf-life extension data (terrestrial data, FDA – can 
include)
– Mass, dimensions of packaging
– Spaceflight usage data (citation or summary)
– Spaceflight stability data (citation or summary)
– Analog environment stability data (citation or summary)
– Spaceflight PK/PD data (citation or summary)
– Analog environment PK/PD data (citation or summary)
– References for above data
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Categorize Meds on Exploration Candidate Formulary
• Create systematic, traceable, 
repeatable process for 
assigning each medication to 
a color category
• Further characterize all 
“yellow” medications
– Gateway
– ISS
– NSRL
– Accelerated stability 
– FDA data
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Flight Study of Medications
• Study “yellow” medications
• Arms for different 
packaging/storage strategies
• Phased return of samples 
over time
• Consider other 
environmental interactions
– Radiation shielding
– CO2
– Temp/humidity
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PK/PD, Pharmacogenomics
• PK/PD
– Pharmacokinetics (PK)- body’s effects on the drug
– Pharmacodynamics- drug’s effects on the body
– As physiology changes in flight, the effects of the body on the drug and the drug on the body may change
– Limited quality and quantity of evidence
• Pharmacogenetics/Pharmacogenomics
– Tailoring of medication choice, dosing, and schedule to individuals’ specific –omics profile
– Currently test individual crewmember susceptibility to sleep/wake meds
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Questions?
